Systemic administration to the severe SMA model (Smn1−/−; SMN2) at postnatal day (PND) 0 and 3 of a 160 μg/g/injection of ASO-10-27 resulted in life extension from <12 days to a median survival of 248 days [28]. Here, SMN1 is linked to proximal spinal muscular atrophy.